Nektar Therapeutics Depreciation
Nektar Therapeutics (NKTR) reported Depreciation of $13.20 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2017-03-01
- Nektar Therapeutics depreciation for fiscal 2016 was $13.20M, a 15.79% increase from fiscal 2015.
- Nektar Therapeutics depreciation for fiscal 2015 was $11.40M, a 2.56% decline from fiscal 2014.
- Nektar Therapeutics depreciation for fiscal 2014 was $11.70M, a 10.00% decline from fiscal 2013.
- Nektar Therapeutics depreciation for fiscal 2013 was $13.00M, a 5.80% decline from fiscal 2012.
| Period end | Depreciation 12 month |
|---|---|
| 2016-12-31 | $13.20M 10-K · filed 2017-03-01 |
| 2015-12-31 | $11.40M 10-K · filed 2017-03-01 |
| 2014-12-31 | $11.70M 10-K · filed 2017-03-01 |
| 2013-12-31 | $13.00M 10-K · filed 2016-02-29 |
| 2012-12-31 | $13.80M 10-K · filed 2015-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |